RENAL TRANSPLANTATION HAS

ORIGINAL CONTRIBUTION Arterial Hypertension and Renal Allograft Survival Kevin C. Mange, MD Borut Cizman, MD Marshall Joffe, MD, PhD Harold I. Feldman, MD, MSCE Context Several observational studies have investigated the significance of hypertension in renal allograft failure; however, these studies have been complicated by the lack of adjustment for baseline renal function, leaving the role of elevated blood pressure in allograft failure unclear. Objective To examine the relationship between blood pressure adjusted for renal function and survival after cadaveric allograft transplantation. Design Nonconcurrent historical cohort study conducted from 1985 through 1997. Setting University teaching hospital. Participants A total of 277 patients aged 18 years or older who underwent cadaveric renal transplantation without another simultaneous organ transplantation and whose allograft was functioning for a minimum of 1 year. Follow-up continued through 1997 (mean follow-up, 5.7 years). Main Outcome Measure Time to allograft failure (defined as death, return to dialysis, or retransplantation) by systolic, diastolic, and mean arterial blood pressure measurements at 1 year after transplantation. Results Multivariate Cox proportional hazards modeling demonstrated that nonwhite ethnicity, history of acute rejection, and nondiabetic kidney disease were significant predictors of failure (P =.01 for all). In addition, the calculated creatinine clearance at 1 year had an adjusted rate ratio (RR) for allograft failure per 10 ml/min (0.17 ml/s) of 0.74 (95% confidence interval [CI], 0.62-0.88). The RR per 10-mm Hg increase in blood pressure measured at 1 year after transplantation, after adjustment for creatinine clearance, was 1.15 (95% CI, 1.02-1.30) for systolic pressure, 1.27 (95% CI, 1.01-1.60) for diastolic pressure, and 1.30 (95% CI, 1.05-1.61) for mean arterial pressure. Supplemental analyses that did not include death as a failure event or reduce the minimum allograft survival time for study subjects to 6 months yielded results consistent with the primary analysis. There was no evidence of modification of the blood pressure allograft failure relationship by ethnicity or diabetes mellitus. Conclusions Systolic, diastolic, and mean arterial blood pressures at 1 year posttransplantation strongly predict allograft survival adjusted for baseline renal function. More aggressive control of blood pressure may prolong cadaveric allograft survival. JAMA. 2000;283:633-638 www.jama.com RENAL TRANSPLANTATION HAS emerged as the treatment of choice for many patients with end-stage renal disease. 1 However, despite marked improvements in short-term allograft function with administration of newer potent immunosuppressive medications, long-term allograft survival continues to be inadequate, with allograft failure being one of the most important reasons for (re) initiating long-term dialysis treatment in the United States. Nonimmunological factors have been increasingly identified as potentially important mediators of reduced longterm renal allograft function known as chronic allograft nephropathy. 2,3 One such factor is hypertension; higher blood pressures have been observed among patients whose allografts failed the most rapidly. 4,5 These observations are consistent with the recent demonstration of a graded risk of developing end-stage renal disease with increasing levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP) outside of the transplant setting. 6 However, it has been difficult to establish the exact role of hypertension in chronic allograft dysfunction, because elevations in blood pressure frequently occur as a result of the progressive allograft failure that typifies chronic allograft nephropathy. Prior studies of the relationship between hypertension and renal failure have not been able to control for baseline renal function and therefore have left unanswered the question of whether elevations in blood pressure are a cause or a result of progressive renal dysfunction. Further complicating the evaluation of the role of hypertension as a cause of progressive allograft dysfunction is the potential effect of certain classes of antihypertensive agents on renal function independent of their effect on blood pressure. For example, calcium channel blockers have been shown to limit the renal arteriolar vasoconstriction induced by cyclosporine, 7,8 and angiotensin-converting enzyme inhibitors have been shown to reduce the rate of progression of renal Author Affiliations: Center for Clinical Epidemiology and Biostatistics and the Department of Biostatistics and Epidemiology, University of Pennsylvania Medical Center (Drs Mange, Cizman, Joffe, and Feldman), and Renal Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania (Drs Mange, Cizman, and Feldman), Philadelphia. Corresponding Author and Reprints: Harold I. Feldman, MD, MSCE, University of Pennsylvania Medical Center, 423 Guardian Dr, 720 Blockley Hall, Philadelphia, PA 19104-6021 (e-mail: hfeldman@cceb.med.upenn.edu). 2000 American Medical Association. All rights reserved. JAMA, February 2, 2000 Vol 283, No. 5 633

failure in native kidney disease, possibly by decreasing intraglomerular hypertension. 9 A clearer understanding of the etiologic role of hypertension in chronic allograft nephropathy is critical to developing optimal strategies for management of hypertension among transplant recipients. The principal objective of this study was to characterize the relationship between hypertension and subsequent kidney allograft failure, adjusting for baseline allograft function and other potential confounding factors, thereby accounting for the elevations in blood pressure that result from allograft dysfunction. METHODS We performed a historical cohort study among adult recipients of cadaveric kidneys that examined the relationship of blood pressure and long-term allograft survival adjusted for renal function. A secondary aim was to evaluate the potential impact of specific classes of antihypertensive agents on allograft survival. Subjects All patients aged 18 years or older who underwent cadaveric renal transplantation at the Hospital of the University of Pennsylvania between January 1, 1985, and December 31, 1990, were eligible for this study. From 1985 to 1990, a total of 376 cadaveric transplantations were performed at the hospital. Study subjects were limited to the 277 patients who underwent kidney transplantation without another simultaneous organ transplant and whose kidney allograft was functioning 1 year after cadaveric renal transplantation. We excluded patients whose allografts failed during the first year following transplantation because allograft failure occurring during this period is commonly due to processes (eg, surgical complications and hyperacute rejection) that are not likely to be modified by blood pressure control. The research protocol was approved by the Institutional Review Board of the University of Pennsylvania. Organ Procurement All kidney allografts were procured using standard multiorgan intravascular flush techniques and preserved at 4 C until implantation. Pulsatile perfusion was not used. In most cases, the aorta of the donors was flushed with Euro-Collins solution. Harvested kidneys were cold-stored in Euro-Collins solution (Electrolyte Solution for Kidney Preservation; Baxter Health Care, Irvine, Calif). Immunosuppression All patients received triple immunosuppression consisting of corticosteroids, cyclosporine, and azathioprine. One gram of methylprednisolone was administered intraoperatively, followed by prednisone, 1.5 mg/kg per day, tapered to 0.5 mg/kg per day by discharge. By 6 months, the prednisone dosage was lowered to 0.15 mg/kg per day. Cyclosporine administration was begun on the first postoperative day at 14 mg/kg per day to maintain a whole-blood trough level between 100 and 200 mg/l by high-performance liquid chromatography. If allograft function was delayed, the cyclosporine was lowered to 7 mg/kg per day until renal function began. Azathioprine was administered intraoperatively at a dosage of 10 mg/kg per day and then tapered to 1 mg/kg per day by day 5 postimplantation. In 1988, 27 patients with oliguria received cyclosporine-sparing therapy with antibody induction for the first 7 to 14 days after transplantation. Study Data The primary outcome was allograft failure as defined by return to dialysis, repeat transplantation, or death. Allograft outcomes were obtained from the United Network for Organ Sharing and medical records. Potential confounding variables were abstracted from subjects charts: HLA antigens recorded as the number of HLA-A, HLA-B, and HLA-DR mismatches; panel of reactive antibodies as a continuous variable from 0% to 100%; age; sex; ethnicity (white, African American, Hispanic, or other); primary cause of renal failure (diabetes mellitus, hypertension, glomerulonephritis, or other); delayed allograft function defined as the need for dialysis within 1 week of transplantation; and the number of acute rejections within the first year. Serum creatinine and SBP and DBP were recorded at 12 months. Twelve months was chosen a priori because we hypothesized that by this time following transplantation additional episodes of acute rejection with their associated destabilizing effect on renal function would be uncommon. In addition, by 12 months immunosuppressive therapy is usually stabilized. Mean arterial blood pressures (MABPs) were calculated by the formula (SBP DBP)/3 + DBP. Glomerular filtration rates were estimated using creatinine clearances calculated using the formula described by CockcroftandGault 10 :(140 age[inyears]) weight[inkilograms])/(72 serumcreatinine) ( 0.85 for women). Exposure to angiotensin-converting enzyme inhibitors or calcium channel blockers was defined as the use of 1 of these agents any time between 3 and 12 months following transplantation. Statistical Analysis The primary analysis examined the relationship between SBP, DBP, and MABP at 1 year following transplantation and long-term allograft survival. Initially, baseline characteristics at 1 year after transplantation including ethnicity, age, sex, percentage reactive antibodies, HLA mismatches, and primary cause of renal disease were described by mean, median, and SD for continuous variables and frequencies for nominal variables. We used the Cox proportional hazards model to examine the relationship of blood pressure and other baseline covariates to allograft survival. 11 We first examined the unadjusted associations of these variables with allograft survival. Variables that had a nominally significant relationship to allograft survival (P.20) were considered as candidates 634 JAMA, February 2, 2000 Vol 283, No. 5 2000 American Medical Association. All rights reserved.

for multivariate model building. We fit these multivariate models by first adding covariates in a forward stepwise manner and then removing variables that did not retain statistical significance (P.10) by means of a backward algorithm. The potential nonlinear relationship of SBP, DBP, and MABP to allograft failure was explored using indicator variables for the quartiles of the pressure measurements. To account for possible nonlinearity of blood pressure in our models, quadratic terms were also examined. In addition, a number of interactions were explored, including those between blood pressure and race as well as between blood pressure and diabetes. The proportionality assumption underlying Cox proportional hazards regression was tested in 2 manners. First, Ln( Ln[S{t}]) curves were examined to affirm that the survival functions remained parallel over time. 12 Second, a 2 test based on weighted residuals was performed. 13 Both approaches confirmed the proportionality assumption for each of our measures of blood pressure in unadjusted and adjusted models. In an exploratory analysis of antihypertensive agents and allograft survival, subjects exposed to an angiotensin-converting enzyme inhibitor were compared with those subjects who were not exposed to this agent, and subjects exposed to a calcium channel blocker were compared with those patients who were not similarly exposed. Multivariate models were fit to evaluate the association of antihypertensive agent class and allograft survival using methods similar to those for the principal analysis of blood pressure and kidney allograft function. All statistical analyses were performed using Intercooled Stata, Version 5.0 (Stata Corp, College Station, Tex). RESULTS Descriptive Analyses Among the 277 patients eligible for this study, more than 60% were men and had kidney disease due to glomerulonephritis (TABLE 1). The majority of the recipients were white (71.5%); 23.8% were African American, and 4.7% were either Asian or Hispanic. Few recipients were highly immunologically sensitized (mean panel reactive antibodies were 10.9%, and 10.5% of recipients had prior kidney transplants), although more than 90% received kidneys that were mismatched at more than 3 HLA loci. Delayed allograft function occurred for 46.4% of recipients, and 62.6% of recipients had an episode of acute rejection within the first year following transplantation. The mean (SD) follow-up time was 5.73 (2.4) years. By the end of the study, 13.0% of patients had died with a functioning allograft, 20.5% had received another transplant or returned to dialysis, and 66.5% had not experienced an end point by the time of their last known follow-up. The mean (SD) duration of follow-up for this latter group was 6.12 (3.22) years. At 12 months following transplantation, the mean (SD) creatinine clearance for all study subjects was 0.88 (0.37) ml/s (53 [22] ml/min) and the average (SD) MABP was 104 (13) mm Hg. The relationship between blood pressure and the level of renal function measured by the creatinine clearance at 1 year (in quartiles) is shown in TABLE 2. The MABP, mean SBP, and mean DBP for each of the quartiles of renal function are provided. For each of these measures of blood pressure, lower creatinine clearance was associated with higher blood pressures. Analysis of Allograft Survival As an initial exploration of the unadjusted effect of blood pressure on allograft survival, Kaplan-Meier curves were generated separately for tertiles of SBP, DBP, and MABP (FIGURE). Systolic blood pressure (P =.009) and MABP (P =.02) had statistically significant unadjusted associations with allograft survival, whereas the association of DBP did not achieve conventional levels of significance (P =.20). The unadjusted association between potential confounding variables and allograft failure was examined in bivariate proportional hazards models (TABLE 3). Variables consid- Table 1. Characteristics of the 277 Allograft Recipients With a Minimum Allograft Survival of 12 Months* Age, y 41.2 (11.98) Ethnicity, % White 71.5 African American 23.8 Sex, % men 61.9 Native kidney disease, % Diabetes mellitus 15.4 Hypertension 13.9 Glomerulonephritis 37.3 Other 33.5 Prior kidney transplant, % 10.5 Panel reactive antibodies, % 10.9 (24) HLA antigen mismatches, % 0 1.4 1-2 7.6 3-4 49.5 5-6 41.5 Cold ischemia time, h 29.6 (8.1) Induction therapy, % 7.5 Delayed graft function, % 46.4 Acute rejection in first year, % 62.6 Systolic blood pressure at 140.8 (19.6) 12 mo, mm Hg Diastolic blood pressure at 85.7 (11.4) 12 mo, mm Hg Mean arterial blood pressure at 104 (12.5) 12 mo, mm Hg Calculated creatinine clearance 0.88 (0.35) at 12 mo, ml/s Body surface area at 12 mo, m 2 1.88 (0.3) *Data are presented as mean (SD) unless otherwise indicated. To calculate ml/min, divide by 0.01667. Table 2. Blood Pressure and Creatinine Clearance at 12 Months Posttransplantation for Each Quartile of Renal Function* Creatinine Clearance at 12 mo, ml/s Blood Pressure, Mean (SD), mm Hg Quartile Range Mean (SD) SBP at 12 mo DBP at 12 mo MABP at 12 mo 1 0.24-0.61 0.48 (0.10) 145.0 (18.2) 88.2 (12.5) 107.2 (12.8) 2 0.62-0.82 0.73 (0.05) 143.3 (18.7) 85.9 (9.4) 105.0 (11.0) 3 0.83-1.07 0.94 (0.07) 142.3 (23.6) 85.0 (12.6) 104.1 (14.0) 4 1.08-2.56 1.37 (0.32) 133.7 (16.1) 84.2 (11.1) 100.7 (11.8) *SBP indicates systolic blood pressure; DBP, diastolic blood pressure; and MABP, mean arterial blood pressure. To calculate ml/min, divide by 0.01667. P.001. P.09. P.01. All P values derived by 2 test for trend for overall categories (SBP, DBP, and MABP). 2000 American Medical Association. All rights reserved. JAMA, February 2, 2000 Vol 283, No. 5 635

Figure. Kaplan-Meier Curves of Allograft Survival by Blood Pressure Tertile Lower Tertile Middle Tertile Upper Tertile Proportion of Allografts Surviving 1.00 0.75 0.50 0.25 0 Systolic Blood Pressure at 1 Year 1.00 0.75 0.50 0.25 0 Diastolic Blood Pressure at 1 Year 1.00 0.75 0.50 0.25 0 Mean Arterial Blood Pressure at 1 Year 0 500 1000 1500 2000 2500 3000 3500 4000 0 500 1000 1500 2000 2500 3000 3500 4000 0 500 1000 1500 2000 2500 3000 3500 4000 Allograft Survival, d Allograft Survival, d Allograft Survival, d Allograft survival is expressed as days beyond the first year of allograft function. Log-rank test for systolic blood pressure, P=.009. Log-rank test for diastolic blood pressure, P =.20. Log-rank test for mean arterial blood pressure, P =.02. Table 3. Unadjusted Rate Ratios Between Various Variables and Allograft Failure Variable Rate Ratio (95% CI)* P Value Sex (male vs female) 0.99 (0.66-1.49).97 Ethnicity (nonwhite vs white) 3.05 (2.03-4.58).01 Age, per year 0.99 (0.97-1.01).27 Native kidney disease (no diabetes vs diabetes) 0.68 (0.43-1.09).12 Prior renal transplant (any vs none) 2.45 (1.50-4.00).01 Prior blood transfusion, No. ( 5 vs 5) 1.01 (0.97-1.05).56 HLA mismatches, No. ( 3 vs 3) 0.81 (0.50-1.28).36 HLA-DR mismatches (any vs none) 0.71 (0.42-1.21).21 Cold ischemia time, per hour 0.98 (0.95-1.01).15 Antibody induction (yes vs no) 1.58 (0.82-3.04).20 Delayed graft function (yes vs no) 1.37 (0.91-2.07).13 Acute rejection (any vs none in first year) 2.35 (1.45-3.83).01 Creatinine clearance at 12 mo, per 0.17 ml/s 0.65 (0.56-0.77).01 Systolic blood pressure at 12 mo, per 10 mm Hg 1.22 (1.09-1.36).01 Diastolic blood pressure at 12 mo, per 10 mm Hg 1.25 (1.01-1.55).05 Mean arterial blood pressure at 12 mo, per 10 mm Hg 1.36 (1.11-1.65).01 Body surface area, per m 2 1.77 (0.63-4.98).28 *CI indicates confidence interval. Rate ratios were calculated with Cox proportional model. ered to be candidates for multivariate models included ethnicity, history of a prior renal transplant, acute rejection, SBP, DBP, MABP, and creatinine clearance at 1 year after transplantation. Ethnicity, a history of nondiabetic renal disease, as well as acute rejection within the first year all independently predicted allograft failure in our multivariate model (TABLE 4). The level of renal function at 1 year predicted survival. When SBP, DBP, and MABP at 1 year were added separately to the model containing the creatinine clearance at 1 year, the rate ratio for each of these representations of blood pressure continued to predict allograft survival (TABLE 5). For each 10-mm Hg increment in SBP, DBP, and MABP, there were 15%, 27%, and 30% reductions, respectively, in the rate of allograft survival. When we fit models that combined measures of blood pressure, there was little evidence of an improved ability of our models to predict allograft survival, particularly for SBP and MABP. Adding SBP to a model with DBP modestly improved its predictive ability (P =.19). We did not detect a nonlinear relationship between blood pressure and allograft survival using either quadratic terms or indicator variables for discrete levels of blood pressure (all P values.20 for the separate addition of quadratic terms for SBP, DBP, and MABP). To assess the stability of our results, we performed a sensitivity analysis in which we considered patient death as a censoring event rather than as a failure. The rate ratios for SBP, DBP, and MABP were 1.12 (95% confidence interval [CI], 0.95-1.31), 1.45 (95% CI, 1.09-1.91), and 1.33 (95% CI, 1.04-1.70), respectively. We also explored for interactions between blood pressure and ethnicity as well as between blood pressure and diabetes mellitus, but were not able to detect any. Use of Antihypertensive Agents We could not detect a relationship between the exposure to angiotensinconverting enzyme inhibitors or to calcium channel blockers within 3 to 12 months posttransplantation and allograft survival in unadjusted analyses or in analyses adjusted for blood pressure and creatinine clearance (P.20 for all analyses). Additionally, we detected no interaction between blood pressure and angiotensin-converting enzyme inhibitors or creatinine at 12 months. COMMENT Thishistoricalcohortstudydemonstrated that SBP, DBP, and MABP at 1 year posttransplantation are statistically and clinically significant predictors of long-term renal allograft survival independent of baseline renal allograft function. The association between blood pressure and al- 636 JAMA, February 2, 2000 Vol 283, No. 5 2000 American Medical Association. All rights reserved.

lograft survival appeared linear without a definite threshold value below which improvements in allograft outcomes no longeroccurred.foreveryincreaseof0.17 ml/s (10 ml/min) in calculated creatinine clearance at 1 year, the adjusted rate of allograft failure decreased by 36%. After adjusting for this potent influence of baseline renal function on allograft survival, we continued to observe a 30% elevation in the rate of allograft failure for every 10-mm Hg increase in MAPB. The results were stable in a number of sensitivityanalyses. Ourfindingsprovideevidence that chronic elevations in blood pressurecauseprogressiverenaldysfunction and that this association is not simply a result of the occurrence of hypertension resulting from progressive renal dysfunction associated with chronic allograft nephropathy. The plausibility of a relationship between chronically elevated blood pressure and allograft function arises from growing evidence of an association between progressive renal disease and hypertension outside of the setting of transplantation. One prior study 14 investigated the rate of decline of renal function among individuals who were enrolled in the Multiple Risk Factor Intervention Trial (MRFIT). Baseline blood pressure and serum creatinine levels and follow-up data for a 6-year period were available for all eligible patients. A multivariate analysis demonstrated that both higher baseline blood pressure and creatinine levels predicted a steeper decline in renal function. A more recent study 5 included all of the men who were screened as well as those who ultimately were enrolled in MRFIT. These individuals were tracked over a period of 16 years for the occurrence of endstage renal disease, and the relationship between baseline blood pressure and end-stage renal disease was estimated. Men who had a screening SBP of 210 mm Hg or greater or a DBP of 120 mm Hg or greater had a relative risk for the development of end-stage renal disease of 22.1 compared with men with SBP of less than 120 mm Hg and DBP less than 80 mm Hg at baseline. Although these studies examined the blood pressure renal function relationship outside of the transplant setting, they provided the foundation for investigations into the role of hypertension in chronic renal allograft nephropathy. The results of our study are consistent with those of a number of prior investigations that have examined the relationship of blood pressure and kidney allograft survival. Most recently, Opelz et al 5 studied 29 751 European recipients of cadaveric kidneys. Using survival analysis, they demonstrated a statistically significant association between elevated SBP and allograft failure. However, for their principal analysis, these investigators could not adjust for baseline (1 year after transplantation) renal function, raising the possibility that renal failure was the cause and not the result of elevated blood pressure. A second study of 135 nondiabetic recipients of cadaveric renal allografts examined the relationship of blood pressure greater than 150/90 mm Hg at 1 year after transplantation to allograft survival. 4 Unadjusted analyses demonstrated that blood pressure greater than 150/90 mm Hg was associated with reduced allograft survival. However, when a multivariable survival model was fit that adjusted for estimated glomerular filtration rate, blood pressure was no longer a significant predictor of allograft survival. Although these findings suggested that hypertension was a result rather than a cause of allograft dysfunction, the small size of this study and the categorization of blood pressure into only 2 groups limit its interpretation. Furthermore, the exclusion of patients with diabetes mellitus and the probable absence of African American patients limit the generalizability of these results. Finally, Cosio et al 15 performed a multivariate analysis of renal allograft survival in which they studied 547 cadaveric transplant recipients and demonstrated a relationship between MABP (averaged over the first 6 months after transplantation) and allograft survival only in African American recipients. Although these analyses were adjusted for the serum creatinine at 6 months, the instability of renal function and blood pressure due to frequent episodes of acute rejection in this time frame may have been the reason no association was observed in white recipients. Our analyses demonstrate that elevated blood pressure adversely affects allograft survival for both African American and white recipients. Our secondary analysis of the effect of calcium channel blockers and angiotensin-converting enzyme inhibitors on allograft outcomes independent of their blood pressure lowering effects did not detect an independent effect. However, a number of limitations hamper our ability to conclude that there is no effect of these agents on Table 4. Multivariate Proportional Hazards Model of Systolic Blood Pressure and Allograft Survival* Variable Rate Ratio (95% CI) P Value Ethnicity (nonwhite vs white) 2.52 (1.46-4.34).01 Native kidney disease (no diabetes vs diabetes) 0.42 (0.22-0.79).01 Prior kidney transplant (any vs none) 2.89 (1.40-5.95).01 Acute rejection (any vs none in first year) 2.65 (1.30-5.41).01 Systolic blood pressure at 12 mo, per 10 mm Hg 1.15 (1.02-1.31).02 Creatinine clearance at 12 mo, per 0.17 ml/s 0.74 (0.62-0.88).01 *CI indicates confidence interval. Table 5. Adjusted Rate Ratio of Allograft Survival for Systolic, Diastolic, and Mean Arterial Blood Pressure From Multivariate Proportional Hazards Models Variable Rate Ratio (95% CI)* P Value Systolic blood pressure at 12 mo, per 10 mm Hg 1.15 (1.02-1.30).02 Diastolic blood pressure at 12 mo, per 10 mm Hg 1.27 (1.01-1.60).04 Mean arterial blood pressure at 12 mo, per 10 mm Hg 1.30 (1.05-1.61).02 *CI indicates confidence interval. Rate ratios adjusted for the covariates included in the model described in Table 4. 2000 American Medical Association. All rights reserved. JAMA, February 2, 2000 Vol 283, No. 5 637

allograft outcomes. First, we could not control for time-varied use of these medications during clinical followup. Plausibly, the use of these medications later in the posttransplantation course than we examined is important for allograft function. Furthermore, we could not exclude confounding by indication. In particular, it is possible that use of these agents differed according to levels of renal function because of demonstrated or hoped for effects on renal function. Finally, the precision of our estimates of effect was low. A number of additional limitations of our study deserve mention. First, the results are applicable only to patients whose allografts have continued to function for more than 1 year. Although we hypothesized that it is unlikely that blood pressure control within the first year of transplantation significantly impacts allografts that fail during the first year, we were not able to examine this hypothesis specifically. Second, we had access to blood pressure readings from 1 clinic visit. While this limited our ability to characterize fully the exposure to hypertension experienced by our patients over the entire follow-up period, this lack of information is likely to have biased our analysis against finding a relationship between blood pressure and allograft function. Indeed, the limited data on blood pressure imply that the relationship between blood pressure and allograft survival may be more potent than we observed. Errors in the measurements of blood pressure are not likely to be associated with subsequent allograft failure, and such nondifferential misclassification would have caused underestimation of the relationship between allograft failure and blood pressure. Third, despite our attempts to control for both immunological and nonimmunological factors influencing allograft function, the possibility remains that we did not fully control for all confounding variables. Finally, studies of the progression of native renal disease have provided evidence that the impact of blood pressure on the progression of kidney dysfunction is greatest among patients with at least moderate elevations in protein excretion. 16 Optimally, we would have been able to examine this issue, but data on protein excretion were not available. In summary, we have demonstrated that blood pressure has a profound impact on allograft outcomes and this effect persists after controlling for baseline renal function. No threshold level of blood pressure was identified below which renal allograft survival failed to improve. Furthermore, we were unable to identify any specific demographic or disease subgroup in which this relationship was not relevant. We were not able to detect an association of specific classes of antihypertensive medications and allograft survival. Ultimately, clinical trials comparing treatment groups randomized to different levels of blood pressure control will be required to confirm the relationships we have described in this study and explore whether more intensive control of blood pressure prolongs renal allograft survival. Funding/Support: The research reported in this article was supported in part by NIH training grant DK- 07006, NIH Center grant DK-45191, National Institutes of Health; and by administrative/educational funds from the Dialysis Clinic Inc Research, Education, and Development Fund. Dr Feldman is an Established Investigator of the American Heart Association. REFERENCES 1. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339-1343. 2. Feldman HI, Fazio I, Roth D, et al. Recipient body size and cadaveric renal allograft survival. J Am Soc Nephrol. 1996;7:151-157. 3. Chertow GM, Milford EL, Mackenzie HS, Brenner BM. Antigen-independent determinants of cadaveric kidney transplant failure. JAMA. 1996;276:1732-1736. 4. Vianello A, Mastrosimone S, Calconi G, Gatti PL, Calzavara P, Maresca MC. The role of hypertension as a damaging factor for kidney grafts under cyclosporine therapy. Am J Kidney Dis. 1993; 21:79-83. 5. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int. 1998;53:217-222. 6. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18. 7. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int. 1993;43:706-711. 8. Chagnac A, Zevin D, Ori Y, Korzets A, Hirsh J, Levi J. The effect of high-dose nifedipine on renal hemodynamics of cyclosporine-treated renal allograft recipients. Transplantation. 1992;53:766-769. 9. Giatras I, Lau J, Levey AS, for the Angiotensin- Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensinconverting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997;127:337-345. 10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41. 11. Cox DB. Regression models and life tables. J R Stat Soc. 1972;34:187-202. 12. Lee E. Statistical Methods for Survival Data Analysis. 2nd ed. New York, NY: John Wiley & Sons; 1992. 13. Gramsch PM, Therneau TM. Propotional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526. 14. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA. 1992;268:3085-3091. 15. Cosio FG, Dillon JJ, Falkenhain ME, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int. 1995;47:1136-1141. 16. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762. 638 JAMA, February 2, 2000 Vol 283, No. 5 2000 American Medical Association. All rights reserved.